Immunovant Inc (IMVT) — Cash Flow-to-Debt Ratio
Immunovant Inc (IMVT) has a Cash Flow-to-Debt Ratio of -1.06x as of June 2026, meaning its operating cash flow of $-124.41 Million could theoretically repay -1% of its total liabilities ($117.10 Million) in one year. See Immunovant Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Immunovant Inc Cash Flow-to-Debt Ratio (2018–2026)
Historical debt coverage capacity for Immunovant Inc across 9 annual periods. For the full cash flow conversion analysis, see how efficiently does Immunovant Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Immunovant Inc (2018–2026)
Year-by-year debt coverage analysis for Immunovant Inc. Check IMVT cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -3.88x | $-407.31 Million | $104.97 Million | ▲ +29.0% |
| 2025 | -5.47x | $-375.87 Million | $68.78 Million | ▼ -24.9% |
| 2024 | -4.38x | $-214.23 Million | $48.95 Million | ▼ -0.8% |
| 2023 | -4.34x | $-188.19 Million | $43.34 Million | ▼ -87.2% |
| 2022 | -2.32x | $-106.11 Million | $45.74 Million | ▲ +41.5% |
| 2021 | -3.97x | $-83.33 Million | $21.01 Million | ▼ -13.9% |
| 2020 | -3.48x | $-53.36 Million | $15.32 Million | ▲ +95.4% |
| 2019 | -75.04x | $-28.55 Million | $380.45K | ▲ +5.8% |
| 2018 | -79.69x | $-128.30 Million | $1.61 Million | — |